This video shows a bladder cancer surgery procedure (Transurethral Resection of Bladder Tumor (TURBT) performed with Blue Light as adjunct to White Light Cystoscopy. With courtesy of Maximillian Burger, Germany
Oslo, Norway, 8 March 2019: Photocure will on Wednesday 13 March 2019 13:00 (CET) stream a Q&A live session with Photocure's President and CEO Dan Schneider via the Facebook group "Photocure Investors" and https://www.facebook.com/groups/aksjekunnskap/ and https://www.facebook.com/groups/Aksjeforum/
It will be open for questions before and during the session. Pål Falck, health analytics at Arctic, will moderate the session.
Oslo, Norway, 27 February 2019: Photocure ASA (OSE:PHO), today reported a revenue growth of 76% in local currency for the U.S. market in the fourth quarter of 2018, contributing to Hexvix/Cysview revenues of NOK 46.3 million (Q4 2017: NOK 39.4) and a recurring EBITDA of NOK -4.1 million (NOK -13.1 million). The company maintains its 2020 forecasted revenue range of USD 20-25 million in the U.S., up from USD 7.8 million in 2018, and sees significant continued revenue growth and profit opportunities in the U.S. market beyond 2020.
Reference is made to the announcement on 14 February 2019 in respect of a capital increase of 17,379 new shares following the execution of the employee long-term incentive program for restricted shares in the company.
Photocure, The Bladder Cancer Company, delivers transformative solutions to improve the lives of bladder cancer patients